Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib

This publication has 16 references indexed in Scilit:

• Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
  Expert Opinion on Investigational Drugs, 2017
• Palbociclib and Letrozole in Advanced Breast Cancer
  New England Journal of Medicine, 2016
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
  New England Journal of Medicine, 2016
• Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model
  Oncotarget, 2016
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
  The Lancet Oncology, 2016
• Giant cell rich osteosarcoma revisited—diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment
  Virchows Archiv, 2016
• Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
  New England Journal of Medicine, 2015
• Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors
  Cancer, 2014
• Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells
  Cancer Letters, 2013
• ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
  Cancer Discovery, 2011